出血性疾患治療薬の世界市場

出血性疾患治療薬の世界市場は2030年までに77億米ドルに達する

2024年に57億米ドルと推定される出血性疾患治療薬の世界市場は、分析期間2024-2030年にCAGR 5.2%で成長し、2030年には77億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである血漿由来凝固因子濃縮製剤は、CAGR 4.3%を記録し、分析期間終了時には19億米ドルに達すると予測されます。遺伝子組換え凝固因子濃縮製剤セグメントの成長率は、分析期間中CAGR 3.6%と推定されます。

米国市場は15億米ドルと推定、中国はCAGR 8.0％で成長予測

米国の出血性疾患治療薬市場は、2024年には15億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに15億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.6%と5.1%と予測されています。欧州では、ドイツがCAGR 3.3%で成長すると予測されています。

世界の出血性疾患治療薬市場- 主要動向と促進要因のまとめ

出血性疾患治療薬が希少疾患治療で世界の注目を集める理由とは？

特に、血友病AおよびB、von Willebrand病、後天性出血性疾患などの希少血液疾患に対する世界の認識と診断が高まり続けているためです。歴史的に、これらの疾患は、診断ツールへのアクセス不足や患者・臨床医双方の限られた認識により、過小診断されてきました。しかし近年、遺伝子スクリーニング、血液学的検査、出生前診断の改善により、早期発見が大幅に増加しています。このような診断の増加に伴い、安全で効果的な、的を絞った治療に対する需要が急増しています。出血性疾患はまれな疾患ではあるが、多くの場合、生涯にわたって影響を及ぼし、自然出血や外傷による出血エピソードを予防・管理するために継続的な薬物介入を必要とします。かつてはゴールドスタンダードであった因子補充療法は、現在では遺伝子組換え凝固因子、非因子補充療法、モノクローナル抗体などの新しい薬剤クラスによって補完あるいは代替されつつあります。また、特定の因子の欠乏や遺伝子変異に基づいて治療法を調整する個別化医療のアプローチも、患者にとって有益なものとなっています。患者支援団体や世界ヘルスイニシアチブを通じた出血性疾患の認知度の向上も、高所得国と発展途上国の両方における政策変更とヘルスケア投資を促進しています。その結果、出血性疾患治療薬の国内処方や保険適用範囲が拡大し、治療がより身近なものとなっています。その結果、出血性疾患治療薬市場はもはやニッチではなく、より広範な希少疾患エコシステムの中で急速に進化する領域と見なされ、製薬大手、研究者、医療政策立案者の注目を集めています。

生物学的製剤と遺伝子治療はどのように治療状況を変えているのか？

出血性疾患の治療法は、生物学的製剤、遺伝子治療、次世代遺伝子組換え療法の登場によって大きく変化しつつあります。従来の治療法は、主に血漿由来または遺伝子組換え凝固因子製剤に基づくものであったが、効果的であるとはいえ、頻繁な点滴が必要であり、多くの場合、週に何度も点滴する必要があったため、患者のコンプライアンス、静脈へのアクセス、生活の質に関する課題がありました。近年、半減期が延長された凝固因子やエミシズマブのような非凝固因子補充療法が標準治療に革命を起こすなど、技術革新の波が押し寄せています。例えばエミシズマブは、皮下投与などはるかに少ない投与回数で出血を予防する素晴らしい効果を示し、治療負担を大幅に軽減しています。さらに画期的なのは、特に血友病AおよびBに対する遺伝子治療薬の出現で、ウイルスベクターを用いて欠陥遺伝子の機能的コピーを挿入することで、長期にわたる、あるいは治癒的な効果をもたらすことを目指しています。valoctocogeneのroxaparvovecやetranacogeneのdezaparvovecのような遺伝子治療の臨床試験は、継続的な因子補充の必要性を減少させるかなくすことに有望であることを示しています。これらの治療法は規制当局によって注視されており、すでに条件付き承認を得ているものや、審査の最終段階にあるものもあります。さらに、RNAベースの薬剤やモノクローナル抗体の進歩は、新しい作用機序を提供し、併用レジメンや代替予防的アプローチへの道を開いています。生物学的製剤や遺伝子治療へのシフトは、臨床転帰を向上させるだけでなく、輸液の繰り返しや入院、関節損傷などの合併症に関連する長期的なヘルスケアコストの削減にもつながっています。この技術革新の波は、出血性疾患治療における有効性、安全性、利便性の新たな基準を打ち立てつつあります。

世界のアクセス、手頃な価格、ヘルスケアインフラはどのように市場力学を形成しているか？

特に、高価格で複雑なロジスティクスを必要とする先進的治療が登場するにつれて、世界のアクセスと手頃な価格は、出血性疾患治療薬市場にとって極めて重要な課題となっています。北米や西欧の患者は最先端の治療に広くアクセスできる恩恵を受けているが、世界の患者人口の大部分（特にアフリカ、アジア、ラテンアメリカ）は依然として血漿由来製剤に頼っているか、一貫した治療を受けるための障壁に直面しています。世界血友病連盟（WFH）をはじめとする世界の医療機関の努力は、寄付された濃縮因子を配布したり、現地の医療インフラ整備を支援したりすることで、このギャップを埋めるのに役立っています。一方、製薬会社は低所得地域における新規治療へのアクセスを拡大するため、段階的価格設定モデルや官民パートナーシップを採用し始めています。出血性疾患治療薬が国の必須医薬品リストに収載され、中所得国での保険適用が拡大されたことも、市場アクセスの拡大に寄与しています。しかし、新しい生物学的製剤や遺伝子治療薬の高額なコスト（1回の治療につき200万米ドルを超えるものもある）は、ヘルスケアシステムにとって依然として大きな課題であり、償還モデルや価値に基づく価格設定をめぐる活発な議論を促しています。ロジスティクスも重要な役割を担っており、治療薬の多くはコールドチェーンでの流通、専門的な投与、長期的なモニタリングを必要とするため、資源に乏しい環境では医療システムの能力が限界に達しています。とはいえ、ヘルスケア・プロバイダーの養成、診断能力の向上、集中治療センターの設立といった現在進行中の取り組みにより、治療提供の改善は着実に進んでいます。こうしたインフラや政策の開発は、世界的にばらつきはあるもの、出血性疾患治療薬がどのように採用され、償還され、国家ヘルスケア戦略に組み込まれるかを形成する上で極めて重要です。

出血性疾患治療薬市場の成長を促進する主な要因は？

出血性疾患治療薬市場の成長は、科学技術革新、人口動向、政策動向など、相互に関連するいくつかの要因によってもたらされます。最も重要な促進要因の1つは、半減期延長因子、モノクローナル抗体、遺伝子治療などの治療技術の急速な進歩であり、これらはより長時間の保護、簡便な投与、患者のアドヒアランスの向上を提供します。より洗練されたスクリーニングプログラムと新生児遺伝子検査に助けられ、診断される出血性疾患の発生率が増加していることが、対処可能な市場を拡大しています。患者の高齢化と慢性出血性疾患患者の平均余命の延長も、長期的な治療に対する持続的な需要に寄与しています。規制面では、希少疾病用医薬品の指定と早期承認の道筋が、特に米国と欧州連合（EU）における新規治療薬の迅速な開発と商業化を可能にしています。専門薬局ネットワークの台頭とバリューベースのヘルスケアモデルへのシフトは、患者支援とアドヒアランスプログラムの充実を促進し、市場の成長をさらに後押ししています。さらに、製薬会社やバイオベンチャーからの旺盛な投資により、臨床開発の様々な段階にある複数の有望な候補化合物からなる競争力の高いイノベーションパイプラインが形成されつつあります。市場の拡大は、出血性疾患治療を支持するヘルスケア政策や資金調達の決定に影響を与える患者アドボカシーの高まりによっても支えられています。教育的な取り組みにより、医療従事者と患者の治療選択肢に対する理解が深まり、新薬の使用率が向上しています。最後に、バイオシミラーの開発により、特にコストに敏感な市場において、特定の治療がより手頃な価格で利用しやすくなると期待されています。これらの促進要因が相まって、ダイナミックで高成長の環境が醸成され、市場力学は固定的な専門領域から希少疾患治療の要へと急速に変貌を遂げつつあります。

セグメント

薬剤タイプ（血漿由来凝固因子濃縮製剤、遺伝子組換え凝固因子濃縮製剤、デスモプレシン、抗線溶薬、フィブリンシーラント、その他の薬剤タイプ）、疾患タイプ（血友病A、血友病B、フォンウィルブランド病、その他の疾患タイプ）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）、エンドユース（病院エンドユース、血友病治療センターエンドユース、調査エンドユース、その他エンドユース）

調査対象企業の例（注目の44社）

• Alexion Pharmaceuticals
• Alnylam Pharmaceuticals
• Amgen Inc.
• Aptevo Therapeutics
• Bayer AG
• Biogen Inc.
• BioMarin Pharmaceutical Inc.
• CSL Behring
• Ferring Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• Grifols S.A.
• Johnson & Johnson
• Kedrion Biopharma
• Novo Nordisk A/S
• Octapharma AG
• Pfizer Inc.
• Sanofi S.A.
• Swedish Orphan Biovitrum AB（Sobi）
• Takeda Pharmaceutical Company Ltd.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Bleeding Disorder Drugs Market to Reach US$7.7 Billion by 2030

The global market for Bleeding Disorder Drugs estimated at US$5.7 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Plasma-Derived Coagulation Factor Concentrates, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Recombinant Coagulation Factor Concentrates segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 8.0% CAGR

The Bleeding Disorder Drugs market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Bleeding Disorder Drugs Market - Key Trends & Drivers Summarized

Why Are Bleeding Disorder Drugs Attracting Heightened Global Focus in Rare Disease Treatment?

Bleeding disorder drugs are becoming a central focus within the pharmaceutical landscape, particularly as global awareness and diagnosis of rare hematologic conditions such as hemophilia A and B, von Willebrand disease, and acquired bleeding disorders continue to rise. Historically, these conditions were underdiagnosed due to lack of access to diagnostic tools and limited awareness among both patients and clinicians. However, recent years have seen a significant uptick in early detection thanks to improvements in genetic screening, hematology testing, and prenatal diagnostics. With this rise in diagnosis, the demand for safe, effective, and targeted treatments has surged. Bleeding disorders, while rare, often have lifelong implications that require continuous drug intervention to prevent or manage spontaneous and trauma-induced bleeding episodes. Factor replacement therapies, once the gold standard, are now being complemented or replaced by newer drug classes, including recombinant clotting factors, non-factor replacement therapies, and monoclonal antibodies. Patients are also benefiting from personalized medicine approaches, which tailor therapies based on specific factor deficiencies or genetic mutations. The increasing visibility of bleeding disorders, through patient advocacy organizations and global health initiatives, is also driving policy changes and healthcare investment in both high-income and developing nations. This has contributed to the broadening of national formularies and insurance coverage for bleeding disorder medications, making treatments more accessible. As a result, the bleeding disorder drugs market is no longer seen as niche but as a rapidly evolving domain within the broader rare disease ecosystem, commanding attention from pharmaceutical giants, researchers, and health policy-makers alike.

How Are Biologic Therapies and Gene Treatments Transforming the Therapeutic Landscape?

The therapeutic landscape for bleeding disorders is undergoing a transformative shift, largely driven by the advent of biologic drugs, gene therapy, and next-generation recombinant therapies. Traditional treatments-largely based on plasma-derived or recombinant clotting factor replacement-while effective, required frequent infusions, often multiple times per week, creating challenges around patient compliance, venous access, and quality of life. Recent years have introduced a wave of innovation, with extended half-life clotting factors and non-factor replacement therapies such as emicizumab revolutionizing the standard of care. Emicizumab, for instance, has shown impressive efficacy in preventing bleeds with far less frequent dosing, including subcutaneous administration, which significantly eases the treatment burden. More revolutionary still is the emergence of gene therapy candidates, particularly for hemophilia A and B, which aim to deliver long-lasting or even curative benefits by inserting functional copies of defective genes using viral vectors. Clinical trials for gene therapies such as valoctocogene roxaparvovec and etranacogene dezaparvovec have shown promise in reducing or eliminating the need for ongoing factor replacement. These therapies are being closely watched by regulators, and some have already received conditional approvals or are in the final stages of review. Additionally, advances in RNA-based drugs and monoclonal antibodies are offering novel mechanisms of action, paving the way for combination regimens and alternative prophylactic approaches. The shift toward biologics and gene therapies is not just enhancing clinical outcomes but also reducing long-term healthcare costs associated with repeated infusions, hospitalizations, and complications like joint damage. This wave of innovation is setting a new standard for efficacy, safety, and convenience in bleeding disorder treatment.

How Are Global Access, Affordability, and Healthcare Infrastructure Shaping Market Dynamics?

Global access and affordability remain pivotal issues in the bleeding disorder drugs market, especially as advanced therapies emerge with high price tags and complex logistical requirements. While patients in North America and Western Europe benefit from widespread access to cutting-edge treatments, large portions of the global patient population-particularly in Africa, Asia, and Latin America-still rely on plasma-derived products or face barriers to any form of consistent treatment. Efforts by global health organizations, including the World Federation of Hemophilia (WFH), are helping to bridge this gap by distributing donated factor concentrates and supporting local health infrastructure development. Meanwhile, pharmaceutical companies are beginning to adopt tiered pricing models and public-private partnerships to expand access to novel therapies in lower-income regions. The inclusion of bleeding disorder treatments in national essential medicines lists and expanded insurance coverage in middle-income countries are also contributing to broader market access. However, the high cost of new biologics and gene therapies-some of which can exceed $2 million per treatment-remains a substantial challenge for healthcare systems, prompting active debates over reimbursement models and value-based pricing. Logistics also play a key role, as many of the therapies require cold-chain distribution, specialized administration, and long-term monitoring-demands that stretch the capabilities of health systems in resource-limited settings. Nonetheless, ongoing initiatives to train healthcare providers, improve diagnostic capabilities, and establish centralized treatment centers are steadily improving care delivery. These infrastructure and policy developments, while uneven globally, are critical in shaping how bleeding disorder drugs are adopted, reimbursed, and integrated into national healthcare strategies.

What Are the Major Drivers Fueling Growth in the Bleeding Disorder Drugs Market?

The growth in the bleeding disorder drugs market is driven by several interrelated factors spanning scientific innovation, demographic trends, and policy developments. One of the most significant drivers is the rapid advancement of therapeutic technologies-including extended half-life factors, monoclonal antibodies, and gene therapies-that offer longer-lasting protection, simplified dosing, and improved patient adherence. The increasing incidence of diagnosed bleeding disorders, aided by more sophisticated screening programs and newborn genetic testing, is expanding the addressable market. Aging patient populations and longer life expectancies among individuals with chronic bleeding conditions are also contributing to sustained demand for long-term treatments. On the regulatory front, orphan drug designations and accelerated approval pathways are enabling faster development and commercialization of novel therapies, especially in the United States and European Union. The rise of specialty pharmacy networks and the shift toward value-based healthcare models are facilitating better patient support and adherence programs, further fueling market growth. Additionally, robust investment from pharmaceutical companies and biotech startups is creating a highly competitive innovation pipeline with multiple promising candidates at various stages of clinical development. Market expansion is also being supported by growing patient advocacy, which is influencing healthcare policy and funding decisions in favor of bleeding disorder care. Educational efforts are enhancing both provider and patient understanding of treatment options, improving uptake of new drugs. Lastly, the development of biosimilars is expected to make certain treatments more affordable and accessible, especially in cost-sensitive markets. Together, these drivers are fostering a dynamic, high-growth environment that is rapidly transforming the bleeding disorder drugs market from a static specialty into a cornerstone of rare disease therapeutics.

SCOPE OF STUDY:

The report analyzes the Bleeding Disorder Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Other Drug Types); Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Other Disease Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel); End-Use (Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Alexion Pharmaceuticals
• Alnylam Pharmaceuticals
• Amgen Inc.
• Aptevo Therapeutics
• Bayer AG
• Biogen Inc.
• BioMarin Pharmaceutical Inc.
• CSL Behring
• Ferring Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• Grifols S.A.
• Johnson & Johnson
• Kedrion Biopharma
• Novo Nordisk A/S
• Octapharma AG
• Pfizer Inc.
• Sanofi S.A.
• Swedish Orphan Biovitrum AB (Sobi)
• Takeda Pharmaceutical Company Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Bleeding Disorder Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Diagnosis of Hemophilia and von Willebrand Disease Throws the Spotlight on Targeted Bleeding Disorder Therapies
  • Increased Use of Recombinant Clotting Factors Spurs Growth in Prophylactic Treatment Adoption
  • Here's How Gene Therapy Trials Are Transforming the Long-Term Outlook for Severe Hemophilia Patients
  • Global Expansion of Newborn Screening Programs Strengthens Early Detection and Treatment Initiation
  • Orphan Drug Incentives and Fast-Track Approvals Accelerate Market Access for Novel Agents
  • Extended Half-Life Products Drive Convenience and Improve Patient Adherence Across Age Groups
  • Here's the Story: How Subcutaneous Administration and Less Frequent Dosing Are Redefining Patient Expectations
  • Innovations in Non-Factor Replacement Therapies Create Competition and Complementarity Within the Drug Class
  • High Cost of Therapies Influences National Procurement Policies and Reimbursement Access
  • Growth in Hemophilia Treatment Centers Expands Reach of Specialized Drugs in Emerging Markets
  • Rising Demand for Personalized Dosing and Pharmacokinetic-Guided Therapy Shapes Product Development
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Bleeding Disorder Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Bleeding Disorder Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Bleeding Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Plasma-Derived Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Plasma-Derived Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Plasma-Derived Coagulation Factor Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Recombinant Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Recombinant Coagulation Factor Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Desmopressin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Desmopressin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Desmopressin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Antifibrinolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Antifibrinolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Antifibrinolytics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Fibrin Sealants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Fibrin Sealants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Fibrin Sealants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hemophilia A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hemophilia A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Hemophilia A by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Hemophilia B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Von Willebrand Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Von Willebrand Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Von Willebrand Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Hemophilia Treatment Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Hemophilia Treatment Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Hemophilia Treatment Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 56: USA Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: USA 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: USA 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: USA 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Canada 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Canada 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Canada 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Japan 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Japan 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Japan 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Japan 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 92: China Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: China 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: China 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: China 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: China 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Bleeding Disorder Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Bleeding Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Europe 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Europe 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Europe 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 119: France Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: France 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: France 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: France 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: France 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Germany 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Germany 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Germany 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Germany 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Italy 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Italy 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Italy 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Italy 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 155: UK Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: UK 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: UK 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: UK 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: UK 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Spain 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Spain 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Spain 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Spain 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Russia 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Russia 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Russia 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Russia 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Bleeding Disorder Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Bleeding Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Australia 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Australia 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Australia 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Australia 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 230: India Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: India 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: India 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: India 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: India 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: South Korea 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: South Korea 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: South Korea 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: South Korea 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Bleeding Disorder Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Bleeding Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Latin America 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Latin America 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Latin America 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Argentina 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Argentina 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Argentina 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Argentina 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Brazil 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Brazil 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Brazil 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Brazil 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Mexico 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Mexico 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Mexico 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Mexico 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Bleeding Disorder Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Bleeding Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 337: Middle East 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 340: Middle East 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 343: Middle East 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 346: Iran 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 349: Iran 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 352: Iran 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 355: Iran 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 358: Israel 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 361: Israel 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 364: Israel 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 367: Israel 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 382: UAE 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 385: UAE 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 388: UAE 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 391: UAE 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Bleeding Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Bleeding Disorder Drugs by Drug Type - Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 406: Africa 16-Year Perspective for Bleeding Disorder Drugs by Drug Type - Percentage Breakdown of Value Sales for Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Bleeding Disorder Drugs by Disease Type - Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 409: Africa 16-Year Perspective for Bleeding Disorder Drugs by Disease Type - Percentage Breakdown of Value Sales for Other Disease Types, Hemophilia A, Hemophilia B and Von Willebrand Disease for the Years 2014, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Bleeding Disorder Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 412: Africa 16-Year Perspective for Bleeding Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Bleeding Disorder Drugs by End-Use - Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 415: Africa 16-Year Perspective for Bleeding Disorder Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Hemophilia Treatment Centers End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION